Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kim Schach is active.

Publication


Featured researches published by Kim Schach.


Urologic Oncology-seminars and Original Investigations | 2018

Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy

Moshe Chaim Ornstein; Claudia Marcela Diaz-Montero; Patricia Rayman; Paul Elson; Samuel Haywood; James H. Finke; Jin S. Kim; Paul G. Pavicic; Marcelo Lamenza; Sarah Devonshire; Priscilla Dann; Kim Schach; Andrew J. Stephenson; Steven C. Campbell; Hamid Emamekhoo; Marc S. Ernstoff; Christopher J. Hoimes; Timothy Gilligan; Brian I. Rini; Jorge A. Garcia; Petros Grivas

BACKGROUND Myeloid derived suppressor cells (MDSC) are heterogeneous immunosuppressive cells with potential predictive and prognostic roles in cancer. The association between MDSC, clinicopathologic factors, and pathologic response in patients with bladder urothelial carcinoma (UC) was explored. METHODS Peripheral blood or tissue were collected from patients with UC undergoing definitive surgery. MDSCs levels were measured in peripheral blood mononuclear cells and fresh tumor tissue. MDSCs were identified by flow cytometry and defined as total MDSC (T-MDSC) CD33+/HLADR-. From this population, 3 subsets were identified: polymorphonuclear-MDSC (PMN-MDSC) defined as CD33+/HLADR-/CD15+/CD14-, monocytic-MDSC (M-MDSC) defined as CD33+/HLADR-/CD15-/CD14+, and immature-MDSC (I-MDSC) defined as CD33+/HLADR-/CD15-/CD14-. MDSC populations were presented as % of live nucleated blood cells. Spearman correlations (r) and Wilcoxon rank sum test were used to assess correlations between MDSC populations, clinicopathologic factors, and pathologic complete response (pCR). RESULTS 85 patients scheduled to undergo cystectomy from February 2015 through Dec 2016 were included. All patients had blood drawn for analysis and 23 patients had residual tumor tissue collected for analysis at the time of surgery. Of these 85, 74 (87%) were men with a median age at diagnosis of 68 (range: 44-87). Pure UC was the most common histology (75%); 28 (35%) patients had prior treatment with intravesical therapy and 36 (42%) were treated with neoadjuvant chemotherapy, primarily gemcitabine plus cisplatin (n = 24). On surgical pathology, 18 (21%) of the patients had pCR, 11 (13%) had positive lymph nodes, and 20 patients (24%) had lymphovascular invasion. Statistically significant associations were found between circulating MDSC levels and pCR rates (P<0.01), absolute neutrophil-lymphocyte ratio (P = 0.008), and histology (P = 0.01). Tumor % M-MDSCs were negatively associated with lymphovascular invasion (P = 0.04). There were no significant correlations between peripheral blood mononuclear cells and tumor MDSC subtypes. CONCLUSIONS Blood and tissue MDSC levels correlate with several clinicopathologic factors and may predict for pCR. Future studies are needed to highlight the role of MDSC in predicting long-term outcomes and to determine the clinical implications of these findings.


Journal of Clinical Oncology | 2016

Correlation of myeloid derived suppressor cell (MDSC) populations with clinicopathologic features in urothelial carcinoma (UC).

Moshe Chaim Ornstein; C. Marcela Diaz-Montero; Pat Rayman; Paul Elson; Samuel Haywood; James H. Finke; Jorge A. Garcia; Brian I. Rini; Andrew J. Stephenson; Steven C. Campbell; Amr Fergany; Hamid Emamekhoo; Marcelo Lamenza; Sylvia Stybor; Kim Schach; Pam Profusek; Allison Janine Tyler; Marc S. Ernstoff; Petros Grivas

434 Background: MDSC are a heterogeneous population of potent immunosuppressive cells with potential predictive/prognostic significance in solid tumors. The association between MDSC and clinicopathologic features in patients (pts) with UC was investigated. Methods: Peripheral blood from 26 non-metastatic UC pts scheduled to undergo cystectomy or nephroureterectomy at Cleveland Clinic was collected. MDSC were enumerated in fresh unfractionated blood (WB) and in peripheral blood mononuclear cells (PBMC). (T)otal MDSC were defined as CD33+/HLADR-; out of T-MDSC, (G)ranulocytic (CD15+CD14-), (M)onocytic (CD15-CD14+) and (I)mmature (CD15-CD14-) MDSC were identified. CD11b MDSC (Linlo/HLADR-/CD33+/CD11b+) were identified in WB. MDSC populations were presented as % of live nucleated blood cells and as absolute numbers from WB. Wilcoxon rank sum test was used to assess associations between MDSC populations and clinicopathologic features. Due to the exploratory nature of the study, p < .10 was considered significa...


Journal of Clinical Oncology | 2016

PD1, PDL1, PDL2 tumor tissue (TT) expression as predictors of response to neoadjuvant chemotherapy (NAC) and outcome in bladder cancer (BC).

Petros Grivas; Hamid Emamekhoo; Paul Elson; Jesse K. McKenney; Homi Zargar; Cristina Magi-Galluzzi; Kim Schach; Nicole DiBiase Brey; Andrew J. Stephenson; Terri McClanahan; Jennifer H. Yearley; Wendy M. Blumenschein; Lakshmanan Annamalai; Brian I. Rini; Jorge A. Garcia


Targeted Oncology | 2018

Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma

Alice Tzeng; C. Marcela Diaz-Montero; Patricia Rayman; Jin S. Kim; Paul G. Pavicic; James H. Finke; Pedro C. Barata; Marcelo Lamenza; Sarah Devonshire; Kim Schach; Hamid Emamekhoo; Marc S. Ernstoff; Christopher J. Hoimes; Brian I. Rini; Jorge A. Garcia; Timothy Gilligan; Moshe Chaim Ornstein; Petros Grivas


Journal of Clinical Oncology | 2018

Immunological correlates of response to immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts).

Alice Tzeng; C. Marcela Diaz-Montero; Patricia A. Rayman; Jin Sub Kim; Paul G Pavicic; James H. Finke; Pedro C. Barata; Marcelo Lamenza; Sarah Devonshire; Kim Schach; Hamid Emamekhoo; Marc S. Ernstoff; Christopher J. Hoimes; Brian I. Rini; Jorge A. Garcia; Timothy Gilligan; Moshe Chaim Ornstein; Petros Grivas


Journal of Clinical Oncology | 2018

Serial changes in PD1/PDL1 expression in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint blockade (CPB).

Alice Tzeng; C. Marcela Diaz-Montero; Patricia A. Rayman; Jin Sub Kim; Paul G Pavicic; James H. Finke; Pedro C. Barata; Marcelo Lamenza; Sarah Devonshire; Kim Schach; Hamid Emamekhoo; Marc S. Ernstoff; Christopher J. Hoimes; Brian I. Rini; Jorge A. Garcia; Timothy Gilligan; Moshe Chaim Ornstein; Petros Grivas


Journal of Clinical Oncology | 2018

Clinicopathologic factors, treatment patterns, and outcomes in micropapillary urothelial carcinoma (UC).

Prateek Mendiratta; Pedro C. Barata; Vadim S. Koshkin; Allan W. Belcher; Jesse K. McKenney; Kim Schach; Sudhir Isharwal; Byron H. Lee; Andrew J. Stephenson; Georges-Pascal Haber; Brian I. Rini; Timothy Gilligan; Moshe Chaim Ornstein; Jorge A. Garcia; Petros Grivas


Urologic Oncology-seminars and Original Investigations | 2017

Myeloid derived suppressor cells (MDSC) correlate with inflammatory biomarkers in metastatic urothelial carcinoma (mUC)

Petros Grivas; C. Marcela Diaz-Montero; Patricia Rayman; Paul Elson; Samuel Haywood; Jin Sub Kim; Paul G. Pavicic; James H. Finke; Brian I. Rini; Andrew J. Stephenson; Marcelo Lamenza; Priscilla Dann; Kim Schach; Sarah Devonshire; Jennifer S. Ko; Amr Fergany; Marc S. Ernstoff; Christopher J. Hoimes; Jorge A. Garcia; Moshe Chaim Ornstein


Journal of Clinical Oncology | 2017

Myeloid derived suppressor cells (MDSC) and inflammatory biomarkers in metastatic urothelial carcinoma (mUC).

Moshe Chaim Ornstein; C. Marcela Diaz-Montero; Patricia A. Rayman; Paul Elson; Samuel Haywood; Jin Sub Kim; Paul G Pavicic; James H. Finke; Brian I. Rini; Andrew J. Stephenson; Marcelo Lamenza; Priscilla Dann; Kim Schach; Sarah Devonshire; Jennifer S Ko; Amr Fergany; Marc S. Ernstoff; Christopher J. Hoimes; Jorge A. Garcia; Petros Grivas


Journal of Clinical Oncology | 2017

Serial measurements of myeloid derived suppressor cells (MDSC) in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint inhibitors (CI).

Moshe Chaim Ornstein; C. Marcela Diaz-Montero; Patricia A. Rayman; Paul Elson; Samuel Haywood; Jin Sub Kim; Paul G Pavicic; James H. Finke; Brian I. Rini; Jihad H. Kaouk; Marcelo Lamenza; Priscilla Dann; Kim Schach; Sarah Devonshire; Jennifer S Ko; Georges-Pascal Haber; Marc S. Ernstoff; Christopher J. Hoimes; Jorge A. Garcia; Petros Grivas

Collaboration


Dive into the Kim Schach's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hamid Emamekhoo

University of Wisconsin-Madison

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge